Top-return investors are increasingly investing in biotech and venture capital stocks amidst ongoing market turbulence. HLB, a biotech company, saw significant purchases after announcing that its cholangiocarcinoma drug received Priority Review designation from the FDA. Other notable investments include Mirae Asset Venture’s backing of Rebellions in a pre-IPO funding round, aligning with government interests. Despite these developments, the broader market remains weak, influenced by geopolitical tensions and substantial net selling by foreign and institutional investors.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://en.sedaily.com/finance/2026/03/30/top-return-investors-load-up-on-biotech-vc-stocks-amid
